{"name":"Editas Medicine, Inc.","slug":"editas-medicine-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxNNjBqUk04OThRVlZ2dFR4Z3VhRHdZdWpGYU5wMjdGN0hSV19OWGRhV2NfOF91MVJBVUVfeEFMSWJrbjJoR05sSFBXLWQwTmhsaHF5bWwxdmtGampINDl3M2x6WjNuOW9zNDdtWmJlSXRVSGE2Z0k3ZmV5LUNUWUZnaG5ha1FVLXBXWnQxQWJsNVVDVG9fMG00ZmRGUQ?oc=5","date":"2026-03-10","type":"earnings","source":"Finviz","summary":"EDIT Stock Up on Narrower-Than-Expected Q4 Loss, Revenues Rise Y/Y - Finviz","headline":"EDIT Stock Up on Narrower-Than-Expected Q4 Loss, Revenues Rise Y/Y","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE5rMi1PSjJUMC1GWHVnMGZrd3BSdjZTODJsZHZ1bHpZMVBidi1kLTl1UkpPbkQxSFkzRGRxelhoTGw0blBJYTd4YzZRTy1LaGlNeklGSG9vVURaVDVOV1VoN1Z1Rk1IOEg4dVVwOHRn?oc=5","date":"2025-11-14","type":"pipeline","source":"Labiotech.eu","summary":"10 gene therapy companies with promising treatments to watch - Labiotech.eu","headline":"10 gene therapy companies with promising treatments to watch","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxOWTV3dnF0X1puSVBSNE56ZXZCQmNDZzZuaWNSckxQRWdzYURMVHRxbHdlT2s2V2J5dng0U1IzZS12R2hEdm5KTW0yTllZMzFzeWh5bWJfMkdhOUk5SXNUcERsNEdzd01LbF9WdmFKZHQ0aG1RcU00SkpEakhteTA0a2VUR3VHT1UtTUdDaw?oc=5","date":"2025-11-12","type":"pipeline","source":"Pharma Voice","summary":"After a lackluster first drug launch, a new CEO is finding Geron’s commercial footing - Pharma Voice","headline":"After a lackluster first drug launch, a new CEO is finding Geron’s commercial footing","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-11-05","type":"pipeline","source":"simplywall.st","summary":"Lacklustre Performance Is Driving Editas Medicine, Inc.'s (NASDAQ:EDIT) 29% Price Drop - simplywall.st","headline":"Lacklustre Performance Is Driving Editas Medicine, Inc.'s (NASDAQ:EDIT) 29% Price Drop","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxPblZ2UUxpU3UxMi1ZamJHWEhOWnVpQVBManNQYmIwN0h0MTlKRmNab0RoYUVHaDRoWU9xSUtVNHB1MEN4MFhvRjRQMXFGd21keXFOSWlMOHdHYU9kR0hwTkNrd3diRDdPM29tOEpVUW5obElJVDZRN1FTN3dRS1BHZE81d3JBM2g0bUo5TlNoZ3ZpWTJKdlA5Tk9XZkh4aDdyazJlSktaSG9vakU?oc=5","date":"2025-07-30","type":"pipeline","source":"Seeking Alpha","summary":"Editas Medicine - Primed For An Unlikely Comeback? It's Not Impossible - Seeking Alpha","headline":"Editas Medicine - Primed For An Unlikely Comeback? It's Not Impossible","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxOV214TU8zM0NBNFNONlM0Si1DaVpQLVNiN1JMMXBtN3hlTmk4ZUdRN3M3aVlpZ1RrQ0x2cUNKOXpEOVpGR1lvOXdETURwZDNnQkFObjRaVzRYX1ViZFZVRWE3U2QtWUIzNENkZ1RwYzV4Smcta3RiUXNySWEyQzRiS3JnSUMzenZ3bXhMYQ?oc=5","date":"2025-05-15","type":"pipeline","source":"Pharma Voice","summary":"A new CFO tasked with taking ‘scrappy’ Editas from last year’s layoffs into new gene editing territory - Pharma Voice","headline":"A new CFO tasked with taking ‘scrappy’ Editas from last year’s layoffs into new gene editing territory","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxOMjJTS1ZPNTdFdzEwUVNsWThtZmpiQ0NBYVdlc2JES0stZkJqYm1DdTh1Sng2c1FacmktMjl5d2dRYVMzMFJCRlZCZThILThrQmFseXVTQlBTMUJQMldmWmkybTRKYXhqczlYMmNCaDVCQ0UtbFVBZ0dEN3ctZy13N21VTXZFSG8?oc=5","date":"2024-10-31","type":"pipeline","source":"finance.yahoo.com","summary":"Is Editas Medicine, Inc. (EDIT) a Promising Gene Editing Stock? - finance.yahoo.com","headline":"Is Editas Medicine, Inc. (EDIT) a Promising Gene Editing Stock?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxObXBpYTN3cGlwNjMwMVpKVkwzNzY0RVNQc0JyWlpBTk1OS1gyMmRUM084SWZjN3ZBSnYydnU4cm9XdXA3Zi0xMkxnUTNwcDZCYXVLUnVQQjlJU05YQWFiTWt1VGhXVUZZY05POWZ3WnR5MDZmalNDX2ZuVWkxX2xNTHhwdjk0bUZzZFRFZG11WHZkazh6Rl9jSEpqeXVqQVgtZW9fcQ?oc=5","date":"2024-10-22","type":"deal","source":"BioPharma Dive","summary":"Editas, changing course again, looks to partner lead CRISPR therapy - BioPharma Dive","headline":"Editas, changing course again, looks to partner lead CRISPR therapy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxOVkEzc2U2YkpZYWVJUUw2azhKeUhNUE9WU3kwb3VGUGxnVXNaWmlNUFZ4akdBcXlPelRUS3hkS09HOFdCQ1d4YlNDbFg5MDU2alRvSWpua2xCTFNBaHZycmd5bTNxenpGT2RCaUFIakZMUkdlSUJiZFpMOEpBM3NaSTZKeElwN3I3XzZ2aklUT1ZLUU9kZmx4bm83SQ?oc=5","date":"2024-10-04","type":"pipeline","source":"Fierce Biotech","summary":"Editas cashes in on portion of Vertex gene editing licensing agreement for $57M - Fierce Biotech","headline":"Editas cashes in on portion of Vertex gene editing licensing agreement for $57M","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiaEFVX3lxTFBhNHZVczRfaHJ4bndTalpBeW1lVm5SVjJSdVUzSU1zMVo2NVZPRkVkZEhNQ0RMeUtzSVlfQUxUMDlncVdEU1lCc0lSSkxtU0Nzd3FqTDF4ZG9RZEozdkFqOFdHdmNMMUQ0?oc=5","date":"2023-11-27","type":"trial","source":"Wiley Online Library","summary":"Defining curative endpoints for sickle cell disease in the era of gene therapy and gene editing - Wiley Online Library","headline":"Defining curative endpoints for sickle cell disease in the era of gene therapy and gene editing","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxOYmhEaTJQS3BwUVpKdUdUcHFsb1M0OHFpc1JrRWZybW5aSFFjQmZGRVZlZ1JDd1AyTWFIek9PeGlMdkNYSnA3ak1Kb2lJV2F0MmNzdzZNY0VfeUNOdVl1aFdWMlFMUmpfY1JobVk3dExPemxlekRWZXVaYnJkLWRxYUpISXNLbUtFdEtac0dMOU15RHVsQ19tRjFqT0oyajRiRkVSRzdn?oc=5","date":"2020-07-29","type":"deal","source":"Contract Pharma","summary":"Catalent Partners with Gene Editing Company Editas - Contract Pharma","headline":"Catalent Partners with Gene Editing Company Editas","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxNelJ0N1Jqb1FKYXlWY2ZVT1NoNlIwZGhJd3psTV8xcVY5U0JuNmpOV3FMUmdNSXpVWGdDTFNMc2tyZm9MYXYtT2ZtbXBxTFdKQWNvekZKcWViRjF5cS11MWgxZUZydktna2FvUjZwTlU1d3lURTFzQnlsXzhseGNfWWltN2FIdWNPN3M1d1hoYjVqX0F3bWRIOG9xU2tuUzVBLW16bjZxSjVOQUdlTEYtbzBqSDNXRUxnUWxHWGpB?oc=5","date":"2017-03-14","type":"pipeline","source":"Editas Medicine","summary":"Allergan and Editas Medicine Enter into Strategic R&D Alliance to Discover and Develop CRISPR Genome Editing Medicines for Eye Diseases - Editas Medicine","headline":"Allergan and Editas Medicine Enter into Strategic R&D Alliance to Discover and Develop CRISPR Genome Editing Medicines f","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}